URUsama Ragab

Usama Ragab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Usama Ragab has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Metabolic Syndrome in Behçets Disease Patients: Keep an Eye on the Eye

    by Tamer A. Gheita, Suzan S. ElAdle, Eiman Abdel Latif, Yousra H. Abdel-Fattah, Emad El Shebini, Iman I. El-Gazzar, Hanan M. El-Saadany, Nermeen Samy, Reem El-Mallah, Mohamed N. Salem, et al.

    Background: Metabolic syndrome (MetS) is characterized by insulin resistance, high blood pres-sure/sugar, dyslipidemia, and obesity. Whether MetS and its components affect the development of Behçet's Disease (BD) remains unclear. Aims: The aim was to determine the frequency of MetS among BD patients and to study its relationship with disease characteristics. Methods: The study included 1028 adult BD patients recruited from 18 specialized rheumatology centers. 51 healthy matched control were considered. Behçet Disease Current Activity Form (BDCAF) and the BD damage index (BDI) were estimated. Adult Treatment Panel-III criteria were used to define MetS. Results: The mean age of patients was 36.8 ± 10.1 years, M:F 2.7:1 and disease duration 7.01 ± 5.2 years. Their mean BDCAF was 5.1 ± 4.6 and BDI 5.5 ± 2.8. MetS was present in 22.8% of patients and in 5.9% of control (3.9 fold higher-risk). Patients with MetS had a significantly increased age at onset (31.8 ± 9.2 vs. 29 ± 8.5 years) and higher frequency of genital ulcers (96.2% vs. 79.7%), skin involvement (73.1% vs. 50.4%), arthritis (48.3% vs. 29.1%) (p<0.0001) and CNS manifestations (18.8% vs. 13%) (p=0.042) compared to those without it. Eye involvement was significantly increased in those with MetS (82.1% vs. 74.2%) (p=0.003) with increased frequency of posterior uveitis (67.1% vs. 43.5%), retinal vessel occlusion (35.9% vs. 21.3%), retinal vasculitis (41.9% vs. 26.4%) (p<0.0001) and vitritis (37.2% vs. 24%) (p=0.001). BDCAF was significantly lower (3.9 ± 4.3 vs. 5.6 ± 4.6) and BDI higher (7.4 ± 2.7vs5 ± 2.6) (p<0.0001). Conclusion: BD patients with MetS are predisposed to mucocutaneous, musculoskeletal, neuropsychiatric and ocular manifestations with consequently increased damage. The involvement of the deeper structures of the eye should alarm rheumatologists to keep in mind that all patients should have an eye examination, especially those with MetS.


  • Clinical Features of COVID-19 Hospitalized Patients with different degree of Proteinuria

    by Ahmed Noaman, Yaser Elhendy, Sameh Hussein Abdel-Hamid, Mahmoud Nabil Kamel, Usama Ragab

    Background: Coronavirus disease-19 (COVID-19) is a lung disease that also negatively affects several organ systems. Patients with COVID-19 frequently have kidney dysfunction. The exact impact of proteinuria and its degree on the clinical outcome of patients with COVID-19 is unclear. Objective: This study aimed to assess the effect of different degrees of proteinuria on the clinical outcome of hospitalized patients with COVID-19. Patients and methods: This study included 100 patients with COVID-19 at Isolation Department, Zagazig University and Al-Ahrar Teaching Hospitals who presented with proteinuria on admission. Patients were divided into two groups based on their urine protein creatinine ratio (UPCR): those with UPCR less than 1gm and those with UPCR greater than 1gm. Results: There is a statistically significant relation between the two groups regarding neutrophil count (p=0.027) (higher in patients with UPCR > 1gm), and lymphocytes (p=0.003) (lower in patients with UPCR > 1gm). There is a statically significant relation between the degree of proteinuria and the incidence of acute kidney injury (p1gm). Conclusion: Proteinuria in COVID-19 hospitalized patients is associated with poor clinical outcomes and could lead to further renal deterioration and AKI, so it is important to screen for it.

  • Study of Urinary Angiotensinogen as an Indicator of Severity of Diabetic Nephropathy in Type 2 Diabetes

    by Usama Ragab, Yaser Abdel Monem Elhendy, Ghada Amr, Ahmed Abdulsaboor, Fady Atalah Labib, Ahmed Noaman

    Background: Urinary angiotensinogen levels are higher in type 2 diabetes patients with nephropathy, a risk factor for developing renal and cardiovascular consequences. However, the potential relationship between serum urine angiotensinogen levels and albuminuria (in terms of its varying concentrations) is not yet established. As a result, we conduct this research. Method: Sixty-six adults with type 2 diabetes were split into three groups, each of which included 22 people based on their degree of albuminuria, in addition to an age- and gender-matched control group of 22 healthy volunteers. Routine laboratory tests and urine angiotensinogen were evaluated in the study groups and correlated to other study parameters. Results: The current study showed that urine angiotensinogen levels are more significant in diabetic patients with higher albuminuria levels, and it was also found to be associated with urinary albumin excretion in diabetic patients with different grades of albuminuria (n = 66, r = 0.666, p<0.001), and it had highly significant validity in the prediction of albuminuria among individuals with diabetes with sensitivity of 88.6%, specificity of 81.8% and accuracy of 86.4%. Conclusions: According to the findings of this study, increased urine angiotensinogen levels were associated with urinary albumin excretion, and elevated urinary angiotensinogen might be utilized as an effective marker for identifying the degree of albuminuria in diabetic individuals.


  • Role of Anti-C1q Antibodies as Indicator of Renal Activity in Systemic Lupus Erythematosus

    by Usama Ragab, Yaser Abdelmonem Elhendy, Heba Hassan Gawish, Mayada Adel Elsadek Ahmed, Ahmed Noaman

    Background: Several investigations have found a correlation between serum anti-C1q autoantibodies and peripheral lymphocyte apoptosis among systemic lupus erythematosus (SLE) patients. Objective: It was to assess correlation between anti-C1q, lupus nephritis and other markers of lupus activity. Patients and Methods: This case-control study was conducted in Internal Medicine Department in cooperation with Clinical Pathology Department. This study was performed on 72 cases and were allocated into three equal groups: SLE with nephritis group, SLE without nephritis group, and control group. Measurements of anti-C1q titers were carried out with by (ELISA) kits. Results: Anti-C1q antibody levels varied significantly amongst the groups. Post hoc test showed that there was a statistical significance increase in anti-C1q among SLE with nephritis compared to SLE who don’t have nephritis and control and among SLE without nephritis compared to control. Anti-C1q antibodies validity to diagnose LN among the studied group showed that anti-C1q at cut off >88.058 ng/ml had sensitivity 75%, specificity 75%, accuracy 75%, PPV of 75% and NPV of 75% in diagnosis of LN among cases groups. Conclusion: Anti-Clq autoantibodies, like other standard markers like renal SLEDAI, correlate with renal flare-ups as well as renal disease activity.

  • Open Access

    Prevalence And Impact of Hyponatremia in Chronic Kidney Disease Patients with Coronavirus Disease 2019

    by Walid Ahmed Ragab Abdelhamid, Michael Edwar, Usama Ragab

    Background: Coronavirus disease 2019 (COVID-19) is frequently associated with hyponatremia. Individuals with history of chronic kidney disease (CKD) are more likely to experience critical complications related to COVID-19. Objective: This study aimed to identify the prevalence and outcomes of admittance of hyponatremia in COVID-19 patients with history of CKD. Patients and Methods: The study involved admitted CKD patients with COVID-19 between January 2021 and April 2021. It was performed at Zagazig University hospital. Subjects were divided according to admittance serum sodium into group 1 with hyponatremia (80 subjects) and group 2 with normonatremia (68 subjects). Hypernatremic patients were excluded. Clinical and laboratory data were collected from all subjects. Patients were observed for the occurrence of acute respiratory failure, and acute renal failure. Additionally, mortality rates were recorded. Results: Patients in group 1 stayed longer in the hospital than in group 2 (p = 0.034). Additionally, they had higher systolic blood pressure records (p < /em> < 0.001). Group 1 had significantly shorter survival and higher incidence rates of acute kidney injury (AKI) than group 2. Finally, multivariate analysis revealed that the significant risk factors for in-hospital mortality in group 1 were older age, longer hospital stay, higher serum potassium, and higher LDH. Conclusion: In our study, hyponatremia affected 54% of CKD patients with COVID-19 and was attributed to higher rates of AKI and in-hospital mortality.